Eiger BioPharmaceuticals, Inc. (EIGR) financial statements (2020 and earlier)

Company profile

Business Address 2155 PARK BOULEVARD
PALO ALTO, CA 94306
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11010042603314
Cash and cash equivalents196132283314
Short-term investments91391032  
Other undisclosed cash, cash equivalents, and short-term investments(0)     
Receivables    0 
Prepaid expense    0 
Other undisclosed current assets5111174
Total current assets:11410242613488
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment1000(0)1
Other noncurrent assets300000
Other undisclosed noncurrent assets    0 
Total noncurrent assets:610001
TOTAL ASSETS:12010243613489
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:16105516
Accounts payable963303
Accrued liabilities742311
Employee-related liabilities    02
Interest and dividends payable     0
Other undisclosed accounts payable and accrued liabilities     (0)
Debt0 2  0
Restructuring reserve    1 
Other undisclosed current liabilities     1
Total current liabilities:17107527
Noncurrent Liabilities
Long-term debt and lease obligation, including:322613  10
Long-term debt, excluding current maturities302613   
Operating lease, liability1
Other undisclosed long-term debt and lease obligation     10
Liabilities, other than long-term debt, including: 0  0 
Other liabilities 0    
Other undisclosed liabilities, other than long-term debt    0 
Other undisclosed noncurrent liabilities   15 (10)
Total noncurrent liabilities:3226131500
Total liabilities:4836202027
Stockholders' equity
Stockholders' equity attributable to parent726723413272
Common stock000000
Additional paid in capital296238141117222219
Accumulated other comprehensive income (loss)0(0)(0)(0) (0)
Accumulated deficit(225)(171)(119)(76)(191)(146)
Total stockholders' equity:726723413272
Other undisclosed liabilities and equity     10
TOTAL LIABILITIES AND EQUITY:12010243613489

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(68)(51)(42)(46)(42)(33)
Operating loss:(68)(51)(42)(46)(42)(33)
Nonoperating income (expense)211(0)00
Investment income, nonoperating210 00
Other nonoperating income (expense)(0)(0)0(0)0(0)
Interest and debt expense(3)(2)(2)(1)(2)(1)
Loss before gain (loss) on sale of properties:(70)(52)(42)(47)(44)(34)
Other undisclosed net loss     (0)
Net loss available to common stockholders, diluted:(70)(52)(42)(47)(44)(34)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(70)(52)(42)(47)(44)(34)
Other comprehensive loss     (34)
Comprehensive loss:(70)(52)(42)(47)(44)(68)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)0(0)0 
Comprehensive loss, net of tax, attributable to parent:(70)(52)(42)(47)(44)(68)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: